Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
When standard treatments fail, combining two or more biologics or JAK inhibitors may be the answer for patients with systemic autoinflammatory diseases. A new study found that over half of refractory patients achieved a complete response with advanced combination therapy (ACT), while also dramatically cutting steroid use. Infections were the main safety concern, but no unexpected or opportunistic infections occurred.
For patients with systemic autoinflammatory diseases (SAIDs) who've exhausted conventional options, combining two or more biologics or JAK inhibitors — known as advanced combination therapy (ACT) — may offer meaningful relief. A retrospective cohort study published in Seminars in Arthritis and Rheumatism followed 38 refractory SAID patients over a median of 60 months, finding that ACT delivered complete responses in more than half of cases.
The most common drug pairings were IL-1 inhibitors with TNF inhibitors or JAK inhibitors. Among patients with sustained success, inflammation markers and steroid doses dropped dramatically — median daily prednisone fell from 20 mg all the way to zero. About a third of regimens eventually lost effectiveness, typically after around 32 months, and switching within the same drug class appeared to help.
By the Numbers
Why it matters: SAIDs are rare, lifelong, and notoriously difficult to manage when they don't respond to standard therapies. This study offers early but encouraging evidence that ACT is a viable — and relatively safe — strategy for the most refractory cases, potentially reshaping how clinicians approach treatment-resistant autoinflammatory disease.
